Angel Rivero Robles
Adult Health · Houston, TXNPI 1467099820
Payments from drug & device makers
Across 157 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$716
- AstraZeneca$428
- Novo Nordisk$355
- AbbVie$260
- Boehringer Ingelheim$199
- Pfizer$185
- plus $964 from 21 others
What the payments were for
- Food & beverage$3,107100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $716 |
| AstraZeneca | 22 | $428 |
| Novo Nordisk | 20 | $355 |
| AbbVie | 14 | $260 |
| Boehringer Ingelheim | 8 | $199 |
| Pfizer | 7 | $185 |
| GSK | 7 | $145 |
| Dexcom, Inc. | 5 | $115 |
| Amgen | 7 | $110 |
| Viiv Healthcare Company | 3 | $82 |
| Gilead | 3 | $57 |
| Exact Sciences | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $42 |
| Antares Pharma, Inc. | 2 | $40 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Abbott | 1 | $24 |
| Novartis | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Bayer | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Halozyme Inc | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
How this compares
$3,107 in reported general payments places this provider in the 80th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 99 | $129,877 |
| OzempicSemaglutide | 61 | $90,651 |
| FarxigaDapagliflozin Propanediol | 35 | $32,295 |
| XareltoRivaroxaban | 22 | $26,349 |
| EliquisApixaban | 24 | $25,543 |
| MyrbetriqMirabegron | 24 | $21,496 |
| ProliaDenosumab | 11 | $18,427 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $17,158 |
| TrulicityDulaglutide | 16 | $17,067 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $14,569 |
| LinzessLinaclotide | 21 | $11,865 |
| VascepaIcosapent Ethyl | 24 | $9,233 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,921 |
| Rosuvastatin Calcium | 260 | $3,349 |
| Valsartan | 93 | $3,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $199 | $129,87799 claims |
| Novo NordiskOzempic | $355 | $90,65161 claims |
| AstraZenecaFarxiga | $428 | $32,29535 claims |
| Johnson & JohnsonXarelto | $17 | $26,34922 claims |
| PfizerEliquis | $185 | $25,54324 claims |
| AmgenProlia | $110 | $18,42711 claims |
| GSKTrelegy Ellipta | $145 | $17,15817 claims |
| Lilly USA, LLCTrulicity | $716 | $17,06716 claims |
| AbbVieLinzess | $260 | $11,86521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 933 adult health providers in Texas.
Other adult health in Houston
- Kacey LyonsHouston$20K
- Rosa RancesHouston$17K
- Claressa RosacinaHouston$17K
- Michelle MartinHouston$15K
- Loren SemonesHouston$14K
- Anthony SantosHouston$13K
- Dashawn ThomasHouston$11K
- Zandra RiveraHouston$11K
- Brandy KhodrHouston$10K
- Janice TranHouston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.